Targeting Cancer Cells Using LNA-Modified Aptamer-siRNA Chimeras

Nucleic Acid Therapeutics

Volumn 25, Issue 6, 2015, Pages 317-322

  Subramanian, Nithya ^a,b   Kanwar, Jagat R ^b   Kanwar, Rupinder K ^b   Krishnakumar, Subramanian ^a  

^a VISION RESEARCH FOUNDATION   (India)

^b DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; EPITHELIAL CELL ADHESION MOLECULE; LOCKED NUCLEIC ACID; SMALL INTERFERING RNA; STATHMIN; SURVIVIN; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; OLIGONUCLEOTIDE; TUMOR ANTIGEN;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CARCINOGENICITY; CELL PROLIFERATION; CHIMERA; CONTROLLED STUDY; DNA MODIFICATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; QUANTITATIVE ANALYSIS; RETINOBLASTOMA; TARGET CELL; GENE SILENCING; GENETICS; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; APTAMERS, NUCLEOTIDE; CELL ADHESION MOLECULES; CELL LINE, TUMOR; GENE SILENCING; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES; RNA, SMALL INTERFERING;

EID: 84947920586     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2015.0550     Document Type: Article

References (42)

1. Urban-Klein B, S Werth, S Abuharbeid, F Czubayko, and A Aigner. (2005). RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 12:461-466.
2. Peer D, P Zhu, CV Carman, J Lieberman, and M Shimaoka. (2007). Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A 104:4095-4100.
3. Davis ME, JE Zuckerman, CH Choi, D Seligson, A Tolcher, et al. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067-1070.
4. Hao H, Y Zhen, Z Wang, F Chen, and X Xie. (2013). A novel therapeutic drug for colon cancer: EpCAM scFv-truncated protamine (tp)-siRNA. Cell Biol Int 37:860-864.
5. Hussain AF, MK Tur, and S Barth. (2013). An aptamer-siRNA chimera silences the eukaryotic elongation factor 2 gene and induces apoptosis in cancers expressing alphavbeta3 integrin. Nucleic Acid Ther 23:203-212.
6. Nishimura Y, H Mieda, J Ishii, C Ogino, T Fujiwara, et al. (2013). Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes. J Nanobiotechnology 11:19.
7. Shigdar S, J Macdonald, O'Connor M, T Wang, D Xiang, et al. (2013). Aptamers as theranostic agents: modifications, serum stability and functionalisation. Sensors (Basel) 13:13624-13637.
8. Kanwar JR, JS Shankaranarayanan, S Gurudevan, and RK Kanwar. (2014). Aptamer-based therapeutics of the past, present and future: from the perspective of eye-related diseases. Drug Discov Today 19:1309-1321.
9. Orava EW, N Cicmil, and J Gariepy. (2010). Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals. Biochim Biophys Acta 1798:2190-2200.
10. Ireson CR, and LR Kelland. (2006). Discovery and development of anticancer aptamers. Mol Cancer Ther 5:2957-2962.
11. Gires O, CA Klein, and PA Baeuerle. (2009). On the abundance of EpCAM on cancer stem cells. Nat Rev Cancer 9: 143; author reply 143.
12. Gonzalez B, S Denzel, B Mack, M Conrad, and O Gires. (2009). EpCAM is involved in maintenance of the murine embryonic stem cell phenotype. Stem Cells 27:1782-1791.
13. Krishnakumar S, A Mohan, K Mallikarjuna, N Venkatesan, J Biswas, et al. (2004). EpCAM expression in retinoblastoma: a novel molecular target for therapy. Invest Ophthalmol Vis Sci 45:4247-4250.
14. Osta WA, Y Chen, K Mikhitarian, M Mitas, M Salem, et al. (2004). EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64:5818-5824.
15. Yamashita T, A Budhu, M Forgues, and XW Wang. (2007). Activation of hepatic stem cell marker EpCAM by Wntbeta-catenin signaling in hepatocellular carcinoma. Cancer Res 67:10831-10839.
16. Shigdar S, J Lin, Y Yu, M Pastuovic, M Wei, et al. (2011). RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci 102:991-998.
17. Song Y, Z Zhu, Y An, W Zhang, H Zhang, et al. (2013). Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture. Anal Chem 85:4141-4149.
18. Subramanian N, V Raghunathan, JR Kanwar, RK Kanwar, SV Elchuri, et al. (2012). Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer. Mol Vis 18:2783-2795.
19. Kanwar JR, K Roy, and RK Kanwar. (2011). Chimeric aptamers in cancer cell-targeted drug delivery. Crit Rev Biochem Mol Biol 46:459-477.
20. Li L, D Xiang, S Shigdar, W Yang, Q Li, et al. (2014). Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells. Int J Nanomedicine 9:1083-1096.
21. Subramanian N, JR Kanwar, P Athalya, N Janakiraman, V Khetan, et al. (2015). EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex. J Biomed Sci 22:4.
22. Sudhakar J, N Venkatesan, S Lakshmanan, V Khetan, S Krishnakumar, et al. (2013). Hypoxic tumor microenvironment in advanced retinoblastoma. Pediatr Blood Cancer 60:1598-1601.
23. El Deeb NM, and E Abdelzaher. (2014). Stem cell markers OCT4 and nestin in laryngeal squamous cell carcinoma and their relation to survivin expression. Pathol Res Pract 210:751-758.
24. Guvenc H, MS Pavlyukov, K Joshi, H Kurt, YK Banasavadi-Siddegowda, et al. (2013). Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res 19:631-642.
25. Kanwar JR, G Mahidhara, K Roy, S Sasidharan, S Krishnakumar, et al. (2015). Fe-bLf nanoformulation targets survivin to kill colon cancer stem cells and maintains absorption of iron, calcium and zinc. Nanomedicine (Lond) 10:35-55.
26. Miceli C, A Tejada, A Castaneda, and SJ Mistry. (2013). Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer. Cancer Gene Ther 20:298-307.
27. Mitra M, M Kandalam, CS Sundaram, RS Verma, UK Maheswari, et al. (2011). Reversal of stathmin-mediated microtubule destabilization sensitizes retinoblastoma cells to a low dose of antimicrotubule agents: a novel synergistic therapeutic intervention. Invest Ophthalmol Vis Sci 52:5441-5448.
28. Nemunaitis J. (2012). Stathmin 1: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets 16:631-634.
29. Baquero MT, JA Hanna, V Neumeister, H Cheng, AM Molinaro, et al. (2012). Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer. Cancer 118:4660-4669.
30. Roy K, RK Kanwar, CHA Cheung, CL Fleming, RN Veedu, et al. (2015). Locked nucleic acid modified bispecific aptamer-targeted nanoparticles carrying survivin antagonist towards effective colon cancer therapy. RSC Adv 5:29008-29016.
31. Dassie JP, XY Liu, GS Thomas, RM Whitaker, KW Thiel, et al. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27:839-849.
32. Subramanian N, JR Kanwar, RK Kanwar, J Sreemanthula, J Biswas, et al. (2015). EpCAM aptamer-siRNA chimera targets and regress epithelial cancer. PLoS One 10:e0132407.
33. Bellaousov S, JS Reuter, MG Seetin, and DH Mathews. (2013). RNAstructure: Web servers for RNA secondary structure prediction and analysis. Nucleic Acids Res 41:W471-W474.
34. Zuker M (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31:3406-3415.
35. Subramanian N, S Navaneethakrishnan, J Biswas, RK Kanwar, JR Kanwar, et al. (2013). RNAi mediated Tiam1 gene knockdown inhibits invasion of retinoblastoma. PLoS One 8:e70422.
36. Brown DA, SH Kang, SM Gryaznov, L DeDionisio, O Heidenreich, et al. (1994). Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 269:26801-26805.
37. Campbell MA, and J Wengel. (2011). Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals. Chem Soc Rev 40:5680-5689.
38. Prall F, C Maletzki, and M Linnebacher. (2010). The EpCAM high/CD44 high colorectal carcinoma stem cell phenotype is not preferentially expressed in tumour buds. Histopathology 56:553-555.
39. Mitra M, M Kandalam, A Harilal, RS Verma, UM Krishnan, et al. (2012) EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy. Mol Vis 18:290-308.
40. Wenqi D, W Li, C Shanshan, C Bei, Z Yafei, et al. (2009). EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer. J Cancer Res Clin Oncol 135:1277-1285.
41. Yamashita T, J Ji, A Budhu, M Forgues, W Yang, et al. (2009). EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136:1012-1024.
42. Subramanian N, JR Kanwar, B Akilandeswari, RK Kanwar, V Khetan, et al. (2015). Chimeric nucleolin aptamer with survivin DNAzyme for cancer cell targeted delivery. Chem Commun (Camb) 51:6940-6943.